Setmelanotide FDA Approved

What It Is

Setmelanotide is a cyclic eight-amino-acid peptide developed by Rhythm Pharmaceuticals as a selective agonist of the melanocortin-4 receptor (MC4R), the terminal receptor of the hypothalamic leptin-melanocortin satiety pathway. It was approved by the U.S. Food and Drug Administration on November 25, 2020, under the brand name Imcivree®, initially for chronic weight management in adults and pediatric patients aged 6 and older with obesity caused by biallelic (homozygous or compound heterozygous) variants in POMC, PCSK1, or LEPR — three rare autosomal recessive conditions that collectively affect fewer than a few hundred genetically confirmed patients in the United States. In June 2022 the indication was expanded to Bardet-Biedl syndrome (BBS), a ciliopathy in which impaired primary-cilium signaling disrupts melanocortin pathway function. In May 2024 the label was further expanded to include patients aged 2 to 5 years based on the VENTURE Phase 3 trial.

Structurally, setmelanotide is a rationally engineered analog of α-melanocyte stimulating hormone (α-MSH), the endogenous MC4R ligand. The molecule carries key modifications — a cyclic disulfide bridge and D-amino acid substitutions — that confer MC4R selectivity and resistance to peptide degradation. The molecular weight is approximately 1,117 Da and the plasma half-life after SubQ injection is approximately 11 hours, supporting once-daily dosing. Administered SubQ, it is supplied by Rhythm Pharmaceuticals as a 10 mg/mL solution in single-patient-use vials for self-injection at home or clinic.

What makes setmelanotide historically significant is that it is the first therapeutic to directly address the biology of specific monogenic and syndromic obesities. Patients with POMC, PCSK1, LEPR, or BBS-related obesity experience profoundly disruptive hyperphagia from early childhood that is fundamentally resistant to diet, exercise, behavioral intervention, and standard pharmacotherapy — because the defect lies in the brain's ability to register satiety rather than in willpower or lifestyle. Setmelanotide operates downstream of the broken upstream signaling by engaging MC4R directly, restoring the signal that says "you are full." For families who have lived with a child who cannot feel satisfied by any amount of food, the effect of setmelanotide on hunger can be transformative in a way that is categorically different from weight loss in common obesity.

Setmelanotide is not indicated for common polygenic obesity. A Phase 2 trial in general obesity produced only modest weight reduction (approximately 5 to 6 percent at 52 weeks) — an effect size substantially below what GLP-1 agonists (semaglutide, tirzepatide) and the newer triple-agonist incretins (retatrutide) achieve in the same setting. This outcome is consistent with the biology: in common obesity, the leptin-melanocortin pathway is fundamentally intact, so adding an MC4R agonist does not rescue a biology that is not broken.

Mechanism of Action

The leptin-melanocortin pathway is the central appetite-regulating circuit of the mammalian hypothalamus. Setmelanotide intervenes at its terminal receptor.

• Leptin-melanocortin satiety pathway — Leptin secreted by adipose tissue crosses the blood-brain barrier and activates leptin receptors (LEPR) on proopiomelanocortin (POMC) neurons in the hypothalamic arcuate nucleus. These POMC neurons cleave the POMC precursor via the enzyme proprotein convertase subtilisin/kexin type 1 (PCSK1) to generate α-MSH, which diffuses to the paraventricular nucleus and activates MC4R on downstream satiety neurons. MC4R activation produces the subjective sensation of fullness and terminates the meal.
• Genetic defects create hyperphagia — Biallelic loss-of-function variants at any upstream step (LEPR, POMC, PCSK1) disable the pathway. Patients do not receive the satiety signal; they experience relentless hunger, hyperphagic eating, and severe early-onset obesity.
• MC4R agonism (primary mechanism) — Setmelanotide binds MC4R on paraventricular-nucleus neurons with high selectivity and agonizes the Gαs-coupled receptor, producing adenylyl cyclase activation and cAMP generation. This restores the terminal satiety signal despite upstream pathway failure. Hunger and caloric intake decrease; body weight follows.
• Selectivity profile — Setmelanotide is selective for MC4R over MC3R, MC1R, MC2R, and MC5R, but the selectivity is not absolute. Residual MC1R agonism in skin melanocytes contributes to the near-universal skin hyperpigmentation during therapy. Residual MC1R activity also means transient increases in pigmented nevus size and darkening are possible.
• Bardet-Biedl syndrome mechanism — In BBS, the underlying defect is primary-cilium dysfunction. Because MC4R and LEPR both traffic through or signal via primary cilia in hypothalamic neurons, ciliopathy indirectly impairs leptin-melanocortin signaling. Direct MC4R agonism bypasses the ciliopathy-driven signaling deficit.
• Energy expenditure — Beyond appetite suppression, MC4R activation modestly increases resting energy expenditure through sympathetic nervous system activation. Contributes to weight loss independently of caloric reduction.
• Sexual function effects — MC4R signaling participates in central sexual arousal pathways. Spontaneous penile erections and disturbances of sexual arousal are documented class effects of MC4R agonism (melanotan-II, bremelanotide) and appear with setmelanotide as well.
• Pharmacokinetics — Daily SubQ administration; Cmax at ~8 hours post-dose; plasma half-life ~11 hours. Steady-state reached in several days of daily dosing. Metabolized by peptidases; no significant CYP450 interactions.
• Pathway-specific therapeutic — Setmelanotide only rescues obesity caused by defects upstream of MC4R. Obesity from MC4R loss-of-function itself (the most common monogenic obesity) has been studied in heterozygous carriers with partial response; homozygous MC4R loss is not expected to respond.

What the Research Shows

Setmelanotide's pivotal evidence base is built on two Phase 3 trials in specific monogenic obesities and one Phase 3 trial in Bardet-Biedl syndrome. The effect magnitude within the approved indications is substantially larger than any general-obesity pharmacotherapy achieves in non-genetic obesity.

• POMC/LEPR deficiency Phase 3 (Clément et al., Lancet Diabetes Endocrinol 2020; PMID 33137293) — Two single-arm, open-label, multicenter Phase 3 trials. POMC cohort (n=10): 80% of evaluable patients (8/10) achieved ≥10% body weight loss at approximately 1 year. Mean BMI reduction 25.6%. Hunger scores substantially reduced. LEPR cohort (n=11): 45% achieved ≥10% body weight loss; mean BMI reduction 12.5%. Basis for 2020 FDA approval.
• Bardet-Biedl / Alström Phase 3 (Haqq et al., Lancet Diabetes Endocrinol 2022; PMID 36356613) — 38 patients enrolled (32 BBS, 6 Alström). Randomized 1:1 to setmelanotide vs placebo for 14 weeks followed by 52 weeks open-label setmelanotide. In patients aged ≥12 with BBS, 32.3% (95% CI 16.7–51.4; p=0.0006) achieved ≥10% body weight loss at 52 weeks. Alström cohort did not achieve statistical significance. Basis for June 2022 FDA approval for BBS.
• VENTURE pediatric Phase 3 (Argente et al., Lancet Diabetes Endocrinol 2023; PMID 37708919) — 12 patients aged 2–5 years with POMC, PCSK1, LEPR, or BBS-related obesity. 52-week open-label. Supported 2024 label expansion to children aged 2 and above.
• Common obesity Phase 2 — Phase 2 in unselected obesity without upstream pathway defect: only ~5–6% weight loss over 52 weeks. Defined the boundary of setmelanotide's utility.
• Quality of life (Kühnen et al., Orphanet J Rare Dis 2022) — Quality-of-life outcomes from the POMC and LEPR Phase 3 trials; significant patient-reported improvement in multiple domains.
• Natural history comparison — Matched-cohort analysis against Barth BBS natural history data (Forsythe et al.) provides supportive evidence that setmelanotide's effect exceeds what the untreated patient trajectory would predict.
• Long-term extension data — Open-label extension data beyond 52 weeks confirms durability of hunger reduction and weight loss over multiple years in continuing responders.
• Hunger reduction as distinct endpoint — Across all trials, patient- and caregiver-reported hunger scores (Daily Hunger Questionnaire) improved more rapidly and reliably than body weight, supporting the conceptual frame that setmelanotide primarily treats hyperphagia with weight loss as secondary outcome.
• Hypothalamic obesity research — Ongoing Phase 3 evaluation in hypothalamic obesity following craniopharyngioma surgery (a different lesion-driven mechanism, not genetic), with published early positive signals (Roth et al., 2023 abstracts).

Human Data

Setmelanotide's human database is narrow but deep — limited in size by the rarity of the target conditions but methodologically rigorous in design.

• NCT02896192 (POMC Phase 3) — 10 patients with biallelic POMC or PCSK1 deficiency. Single-arm, 4-week placebo-controlled withdrawal period, 52-week treatment.
• NCT03287960 (LEPR Phase 3) — 11 patients with biallelic LEPR deficiency. Same design as POMC trial.
• NCT03746522 (BBS/Alström Phase 3) — 38 patients with BBS or Alström syndrome. Randomized placebo-controlled 14-week lead-in followed by 52-week open-label.
• VENTURE (NCT04966221) — Pediatric 2–5 year Phase 3 in MC4R-pathway-associated obesity.
• Hypothalamic obesity Phase 3 — Ongoing study in post-craniopharyngioma hypothalamic obesity.
• Real-world post-marketing — Since 2020 approval, substantial real-world patient-level experience has accumulated through the specialty prescribing channel. Patient registries document durability, sustained hunger reduction, and emergence of long-term adverse event profile consistent with the trial data.
• Case reports in expanded indications — Published case-level evidence in heterozygous POMC variant carriers, patients with SIM1 variants, and select other MC4R-pathway disorders; outcomes are variable and framed as investigational.
• Pediatric safety extension — Open-label extension of POMC/LEPR trials in pediatric patients supporting continued dosing safety and durability.
• Common obesity Phase 2 (negative) — The negative common-obesity Phase 2 is itself informative: it established the limits of the indication and guided Rhythm's pivot to the precision-medicine approach.

Setmelanotide is therefore a case study in precision-medicine drug development: a mechanistically rational compound with modest effect in the general population but transformative effect in a precisely defined genetic subpopulation.

Dosing from the Literature

Setmelanotide dosing is defined by the FDA-approved Imcivree® label. Titration is used in all age groups to minimize nausea and adverse events during initiation.

Reconstitution & Storage

Imcivree® is supplied by Rhythm Pharmaceuticals as a sterile solution in single-patient-use multidose vials at 10 mg/mL. It does not require reconstitution and is not available as a lyophilized powder. The product ships cold-chain and is stored refrigerated.

• Storage (unopened) — Refrigerate at 2–8°C (36–46°F) in the original carton to protect from light. Do not freeze. Do not shake.
• Storage (in-use) — Once opened, vial may be stored at controlled room temperature (20–25°C) or refrigerated; use within 28 days and discard whatever remains.
• Injection technique — SubQ in abdomen (not within 2 inches of navel), front of thigh, or back of upper arm. Rotate sites. 29–31G insulin syringe for accurate small-volume dosing.
• Timing — Once daily, same time each day. No food restrictions. Morning or evening is acceptable; clinical practice often favors morning dosing for consistency.
• Appearance — Clear and colorless to slightly yellow. Discard if cloudy, discolored beyond specification, or showing visible particulates.

→ Use the Kalios Peptide Calculator for syringe units

Side Effects & Risks

Setmelanotide's adverse event profile is well-characterized from the pivotal trials and post-marketing surveillance.

• Skin hyperpigmentation (very common, ~60%+) — Generalized skin darkening and darkening of existing nevi. Driven by MC1R cross-activation in melanocytes. Expected, reversible after discontinuation, but cosmetically significant. Full dermatologic exam at baseline and periodic monitoring required.
• Injection site reactions — Erythema, pain, pruritus, induration. Common; usually self-limited. Rotate sites.
• Nausea, vomiting, diarrhea — Common during titration; typically mild-to-moderate. Improve over weeks with continued dosing.
• Spontaneous penile erections / sexual arousal disturbance — Documented in male trial participants. MC4R signaling contributes to central sexual arousal circuits. Clinicians counsel patients before initiation.
• Depression and suicidal ideation — Warning on the label. Pre-existing depression should be assessed and monitored during therapy. Mood screening at baseline and periodic reassessment is standard practice.
• Pigmented skin lesion changes — Increased size or darkening of nevi. Pre-existing melanoma is a contraindication; full skin exam at baseline and periodic dermatology follow-up required.
• Hypersensitivity reactions — Rare. Local and systemic reactions including rash, urticaria, anaphylaxis-type events reported in post-marketing.
• Headache — Common, typically mild.
• Dreams / sleep changes — Vivid dreams, dream abnormalities reported in some patients.
• Pregnancy — Not recommended. Animal data suggest developmental effects. Discontinue before conception.
• Lactation — Not recommended.
• Drug interactions — Limited. Setmelanotide is a peptide metabolized by peptidases; no meaningful CYP450 interactions.
• WADA status — Setmelanotide is not specifically named on the current WADA Prohibited List but is plausibly assessable under hormone/metabolic modulator categories given its MC4R pathway activity. Competitive athletes should consult their federation.
• Boxed-warning-adjacent considerations — While setmelanotide does not carry a formal FDA boxed warning, the combined profile (skin hyperpigmentation, nevus changes, depression/suicidality, sexual side effects) represents a non-trivial monitoring burden relative to other chronic therapies.

Bloodwork & Monitoring

Monitoring for setmelanotide-treated patients is anchored to the approved label and specialty-obesity-medicine practice.

• Genetic confirmation — Absolute prerequisite. Biallelic POMC, PCSK1, or LEPR variant (for monogenic obesity) or clinical/genetic BBS diagnosis. Genetic-sequencing panel is the gatekeeping diagnostic.
• Baseline full-body skin exam — Dermatology baseline including mapping of existing nevi before initiation. Dermatology reassessment at 6 and 12 months, then annually.
• Depression/mood screening — PHQ-9 or equivalent validated instrument at baseline and periodic intervals. Suicidality direct questioning at each visit during titration and at least quarterly thereafter.
• Weight and anthropometrics — Baseline and monthly during titration; then every 3 months. BMI z-score tracking in pediatric patients.
• Hunger score — Daily Hunger Questionnaire (used in the Phase 3 trials) or caregiver-reported equivalent. Useful for both efficacy tracking and patient counseling.
• Metabolic panel (CMP, fasting lipids, HbA1c) — Baseline and annually. Improvement expected in responders.
• Thyroid function — Baseline.
• Pediatric growth parameters — Height velocity and bone age in growing patients.
• Sexual side effects — Open, non-judgmental inquiry at follow-up visits, particularly in male adolescents and adults.

Commonly Stacked With

Setmelanotide is typically used as monotherapy for its specific indication. Adjuncts below describe clinical practice rather than trial-validated regimens.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching setmelanotide often also look at these:

Next Steps

Key References

1. Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970. PMID: 33137293.
2. Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GÁ, Poitou C, Yanovski JA, Mittleman RS, Yuan G, Forsythe E, Clément K, Argente J. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859-868. PMID: 36356613.
3. Argente J, Verge CF, Okorie U, Fennoy I, Kelsey MM, Cokkinias C, Scimia C, Lee HM, Farooqi IS. Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2023. PMID: 37708919.
4. Markham A. Setmelanotide: First Approval. Drugs. 2021;81(3):397-403. PMID: 33638809.
5. Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, Mai K, Blume-Peytavi U, Grüters A, Krude H. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N Engl J Med. 2016;375(3):240-246. PMID: 27468060.
6. Clément K, Biebermann H, Farooqi IS, Van der Ploeg L, Wolters B, Poitou C, Puder L, Fiedorek F, Gottesdiener K, Kleinau G, Heyder N, Scheerer P, Blume-Peytavi U, Jahnke I, Sharma S, Mokrosinski J, Wiegand S, Müller A, Weiß K, Mai K, Spranger J, Grüters A, Blankenstein O, Krude H, Kühnen P. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551-555. PMID: 29736023.
7. Collet TH, Dubern B, Mokrosinski J, Connors H, Keogh JM, Mendes de Oliveira E, Henning E, Poitou-Bernert C, Oppert JM, Tounian P, Marchelli F, Alili R, Le Beyec J, Pépin D, Lacorte JM, Gottesdiener A, Bounds R, Sharma S, Folster C, Henderson B, O'Rahilly S, Stoner E, Gottesdiener K, Panaro BL, Cone RD, Clément K, Farooqi IS, Van der Ploeg LHT. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321-1329. PMID: 29031731.
8. Kühnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, Gnanasakthy A, Poitou C, Krabusch PM, Stewart M, Clément K. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022;17(1):38.
9. Dubern B, Lourdelle A, Clément K. Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers. JCEM Case Rep. 2023;1(3):luad041. PMID: 37908575.
10. Forsythe E, Haws RM, Argente J, Beales P, Martos-Moreno GÁ, Dollfus H, Chirila C, Gnanasakthy A, Buckley BC, Mallya UG, Clément K, Haqq AM. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023;18(1):12.
11. Ryan DH. Setmelanotide: what it means for clinical care of patients with obesity. Lancet Diabetes Endocrinol. 2020;8(12):933-935. PMID: 33137294.
12. Huvenne H, Dubern B, Clément K, Poitou C. Rare Genetic Forms of Obesity: Clinical Approach and Current Treatments in 2016. Obes Facts. 2016;9(3):158-173. PMID: 27241181.
13. US Food and Drug Administration. IMCIVREE (setmelanotide) injection, for subcutaneous use — Full Prescribing Information. Initial approval November 2020; label updates June 2022 and 2024.
14. Rhythm Pharmaceuticals. IMCIVREE® prescribing information and patient support program materials. 2024–2026.
15. ClinicalTrials.gov. Setmelanotide program trial listings: NCT02896192 (POMC), NCT03287960 (LEPR), NCT03746522 (BBS/Alström), NCT04966221 (VENTURE pediatric 2–5 yrs).